Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Camillo Porta

Showing results (181-190 of 388) with videos related to

Pageof 39
Sort By:
Critical Reviews in Oncology/Hematology|June 9, 2019
Management of targeted therapies in cancer patients with chronic kidney disease, or on haemodialysis: An Associazione Italiana di Oncologia Medica (AIOM)/Societa' Italiana di Nefrologia (SIN) multidisciplinary consensus position paperNicola Silvestris, Antonella Argentiero, Laura Cosmai, et al.
The Oncologist|February 6, 2025
Updated overall survival in patients with prior checkpoint inhibitor therapy in the phase III TIVO-3 studyMiguel Zugman, David F McDermott, Bernard J Escudier, et al.
American Journal of Clinical Oncology|April 2, 2004
Docetaxel, carboplatin and concomitant radiotherapy for unresectable squamous cell carcinoma of the head and neck: pharmacokinetic and clinical data of a phase I-II studyMario Airoldi, Luigi Cattel, Giorgio Cortesina, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2007
Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesotheliomaAndrea Sartore-Bianchi, Fabio Gasparri, Arturo Galvani, et al.
Journal of Cellular Biochemistry|February 27, 2016
Endoplasmic Reticulum Ca(2+) Handling and Apoptotic Resistance in Tumor-Derived Endothelial Colony Forming CellsValentina Poletto, Silvia Dragoni, Dmitry Lim, et al.
Journal of Nephrology|July 24, 2015
Renal cancer in kidney transplanted patientsGiovanni M Frascà, Silvio Sandrini, Laura Cosmai, et al.
International Journal of Molecular Sciences|August 6, 2020
Non-Melanoma Skin Cancers: Biological and Clinical FeaturesMauro Cives, Francesco Mannavola, Lucia Lospalluti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2007
Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicinRobert G Gish, Camillo Porta, Lucian Lazar, et al.
BMC Nephrology|May 12, 2026
Multimodal predictions of end stage chronic kidney disease from asymptomatic individuals for discovery of genomic biomarkersSimona Rabinovici-Cohen, Daniel E Platt, Toshiya Iwamori, et al.
The Oncologist|December 28, 2022
Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3Luis Meza, David F McDermott, Bernard Escudier, et al.
Pageof 39

Showing results (181-190 of 388) with videos related to

Sort By:
Pageof 39
Critical Reviews in Oncology/Hematology|June 9, 2019
Management of targeted therapies in cancer patients with chronic kidney disease, or on haemodialysis: An Associazione Italiana di Oncologia Medica (AIOM)/Societa' Italiana di Nefrologia (SIN) multidisciplinary consensus position paperNicola Silvestris, Antonella Argentiero, Laura Cosmai, et al.
The Oncologist|February 6, 2025
Updated overall survival in patients with prior checkpoint inhibitor therapy in the phase III TIVO-3 studyMiguel Zugman, David F McDermott, Bernard J Escudier, et al.
American Journal of Clinical Oncology|April 2, 2004
Docetaxel, carboplatin and concomitant radiotherapy for unresectable squamous cell carcinoma of the head and neck: pharmacokinetic and clinical data of a phase I-II studyMario Airoldi, Luigi Cattel, Giorgio Cortesina, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2007
Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesotheliomaAndrea Sartore-Bianchi, Fabio Gasparri, Arturo Galvani, et al.
Journal of Cellular Biochemistry|February 27, 2016
Endoplasmic Reticulum Ca(2+) Handling and Apoptotic Resistance in Tumor-Derived Endothelial Colony Forming CellsValentina Poletto, Silvia Dragoni, Dmitry Lim, et al.
Journal of Nephrology|July 24, 2015
Renal cancer in kidney transplanted patientsGiovanni M Frascà, Silvio Sandrini, Laura Cosmai, et al.
International Journal of Molecular Sciences|August 6, 2020
Non-Melanoma Skin Cancers: Biological and Clinical FeaturesMauro Cives, Francesco Mannavola, Lucia Lospalluti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2007
Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicinRobert G Gish, Camillo Porta, Lucian Lazar, et al.
BMC Nephrology|May 12, 2026
Multimodal predictions of end stage chronic kidney disease from asymptomatic individuals for discovery of genomic biomarkersSimona Rabinovici-Cohen, Daniel E Platt, Toshiya Iwamori, et al.
The Oncologist|December 28, 2022
Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3Luis Meza, David F McDermott, Bernard Escudier, et al.
Pageof 39